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Objective: To compare the bleeding pattern in women using ethinylestradiol 20 mcg/
drospirenone 3 mg (EE 20 mcg/DRSP 3 mg) in a 24/4-day cyclic regimen with an extended
regimen. Unexpected bleeding/spotting in the extended regimen group was managed by
allowing a 4-day hormone-free interval (HFI).
Methods: This was a randomized, prospective, open-label, multicenter study. Participants
(N = 348) were randomized to receive EE 20 mcg/DRSP 3 mg in either an extended regimen
(EE/DRSPes group) or a 24/4-day cyclic regimen (EE/DRSP24/4 group) and followed for 168
days. In the EE/DRSPes group, a 4-day HFI was allowed whenever unexpected bleeding/
spotting persisted for ≥7 consecutive days. The participants assessed their bleeding daily as
“no bleeding,” “spotting,” or “light,” “moderate,” or “heavy” bleeding according to
a predefined scale.
Results: EE/DRSPes group experienced fewer days of bleeding than those using a 24/4 cyclic
regimen (P < 0.001). After 168 days, 57.5% of women in the EE/DRSPes group achieved
complete amenorrhea (i.e., neither bleeding nor spotting) and 73.9% achieved “no bleeding”
(i.e., no bleeding with or without spotting) during the final 28-day interval of the study
period. Women in the extended group who instituted the 4-day HFI experienced a 94.1% rate
of successful management of unexpected bleeding/spotting.
Conclusion: The use of EE 20 mcg/DRSP 3 mg in an extended regimen resulted in high
rates of amenorrhea and “no bleeding”. Unexpected bleeding/spotting in the EE/DRSPes
group could be managed effectively with a 4-day HFI.
Clinical Trial Registration: International Standard Randomised Controlled Trial Number
(ISRCTN57661673): http://www.controlled-trials.com/isrctn/pf/57661673.
Keywords: bleeding profile, combined oral contraceptives, drospirenone, extended regimen,
low dose oral contraceptive
Introduction
Monthly contraceptive interval has been questioned in recent years because the
artificial bleeding resulting from hormonal withdrawal can be associated with
menstrual-related symptoms.1 Some women wish to avoid monthly bleeding not
only because of the symptoms experienced during this period but also for personal
reasons such as convenience and practicality.2 In response, alternative regimens of
birth control pills, such as extended or even continuous administration of active
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pills, are being used in order to avoid occasional problems
related to the hormone-free interval (HFI).3 Extended regi-
mens for oral contraception refer to the use of active pills
for more than 28 days, without an HFI, including the
continuous use of oral contraceptives and variations such
as inclusion of an HFI every 3 months.4
The occurrence of unexpected bleeding/spotting in users
of extended or continuous regimens is one of the most
common problems associated with this administration
scheme. Although the ideal outcome of these regimens is
amenorrhea, the experience both in clinical practice and in
trials is that the bleeding pattern can be erratic, especially
during the first 6 months of use, but tends to improve as the
duration of treatment increases.5,6 The extended use of dif-
ferent hormonal combinations produces mean rates of ame-
norrhea of 60% to 80% after 6 months of uninterrupted
use.3,7-10
Management of any unexpected bleeding/spotting that
occurs is greatly important for the patient’s adherence to
treatment, and higher rates of amenorrhea are associated
with higher rates of satisfaction.3 Paying special attention
to the possibility of bleeding, particularly during the first
months of the extended regimen, in the initial consultation
is quite effective at minimizing premature discontinuation
of the treatment. However, a therapeutic approach can be
used in situations in which the bleeding persists.
The present study aimed to compare the bleeding pat-
tern during a 168-day course of the combination of ethi-
nylestradiol 20 mcg and drospirenone 3 mg (EE 20 mcg/
DRSP 3 mg) in an extended regimen with that during a 24/
4 cyclic regimen of the same formulation and to examine
the effectiveness of an HFI for the management of unex-
pected bleeding/spotting in women using the extended
regimen.
Methods
This was a randomized, open-label, multicenter study con-
stituting part of the main study with the primary objective
of evaluating menstrual-related symptoms in women using
a contraceptive containing ethinylestradiol 20 mcg and
drospirenone 3 mg in an extended flexible regimen or
a 24/4 cyclic regimen (24/4).11
The 11 Brazilian sites (Jundiaí School of Medicine)
(RB Machado), ABC School of Medicine (LM Pompei),
Federal University of Parana (R Andrade), Botucatu
Medical School (Unesp) (E Nahas), Federal University of
Sao Paulo (C Guazzelli), Federal University of Rio Grande
do Sul (MC Wender), Centro de Pesquisa e Assistência em
Reprodução Humana (CEPARH) (H Maia Filho),
University of Sao Paulo – Ribeirao Preto (RA Ferriani),
PUC Rio Grande do Sul (M Badalotti), Centro Paulista de
Investigaçao Clinica (S Del Debio), Endocrinology Unit
Federal University of Sao Paulo (M Lazaretti Castro)
involved in the study obtained approval from their respec-
tive Research Ethics Committees. All women volunteered
to participate in the study, after detailed information was
provided and the informed consent form was signed,
according to the Declaration of Helsinki.
The participants were women aged 18 to 39 years
whose clinical histories included at least 3 consecutive
regular menstrual cycles, defined as cycles at intervals
between 25 and 35 days with bleeding for 3 to 7 days,
immediately prior to the study. Women using OCP that did
not contain drospirenone according to a regimen of 21
active pills followed by a 7-day HFI were also included
so long as they experienced withdrawal bleeding corre-
sponding to the HFI.
The exclusion criteria were the use of OCP containing
drospirenone, any OCP regimen other than 21/7, or the use
of progestogen-only pills, a levonorgestrel intrauterine
system within 3 months before the start of the study, or
medroxyprogesterone acetate administered as an intramus-
cular depot within 6 months before the start of the study or
any condition in category 2, 3, or 4 of the Medical
Eligibility Criteria for Contraceptive Use of the World
Health Organization (WHO).12
Participants underwent a screening period correspond-
ing to a full menstrual cycle (for non-users of OCP) or
a 28-day treatment cycle (for OCP users). During this
time, they used a diary to record their menstrual symptoms
using the “Daily Symptoms Scale,” a version of the Penn
Daily Symptom Report (DSR)13 (to fulfill the primary
objective of this study protocol) and to complete the
“Bleeding Pattern Registry.”
Treatment regimen assigned to each patient was deter-
mined according to a computer-generated central rando-
mization list. The participants were then distributed among
2 groups using an OCP with a daily dose of ethinylestra-
diol 20 mcg in combination with drospirenone 3 mg: the
extended regimen (also called extended scheduled regi-
men, EE/DRSPes) group, in which the participants used
the combination for 168 consecutive days with the option
of a 4-day HFI for management of persistent unexpected
bleeding/spotting, defined in this protocol as presence of
unexpected bleeding/spotting for 7 or more consecutive
days, and the cyclic regimen (EE/DRSP24/4) group, in
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which the participants used active pills for 24 days with
a 4-day HFI between the packs. The evaluation period was
168 consecutive days for both groups, corresponding to
daily use of the combination for 168 consecutive days by
the women in the EE/DRSPes group and six cycles of 28
days for the EE/DRSP24/4 group.
The bleeding pattern was evaluated from the notes in
the participants’ diary according to the criteria suggested
by the WHO.14 Bleeding was classified as the absence of
bleeding or spotting, bleeding (vaginal bleeding requiring
sanitary protection), and spotting (vaginal bleeding not
requiring sanitary protection). The intensity of bleeding
was graded on a scale of 0 to 4, where 0 was defined as
the absence of bleeding or spotting, 1 as spotting, 2 as
light bleeding (less than usual menstruation), 3 as moder-
ate bleeding (same as usual menstruation), and 4 as heavy
bleeding (heavier than usual menstruation).
Participants randomized to EE/DRSPes group who
exhibited persistent unexpected bleeding/spotting were
allowed a 4-day HFI provided that they had been taking
the medication continuously for at least 28 days since the
beginning of the study. The HFI for treatment of persistent
unexpected bleeding/spotting was optional and was imple-
mented when requested by the patient due to the inconve-
nience caused by the bleeding/spotting. Effectiveness of
the HFI was defined as resolution of the bleeding/spotting,
i.e., cessation of vaginal bleeding for at least 14 days after
the initiation of the 4-day HFI.
The sample size was calculated from the primary effi-
cacy parameter (mean percent decrease in the total symp-
tom score assessed by the Penn Daily Symptom Report),
which is the primary objective of the published study.11
Considering an expected improvement of 50% from base-
line, a power of 80%, a significance level of 5%, and
a non-inferiority margin of 15%, 276 patients were sup-
posed to complete the study, assuming a standard devia-
tion of 50%. Considering a 25% dropout rate, at least 368
women were supposed to be enrolled in the study. We
would like to stress that, regarding sample size, if the
study was outlined primarily for the analysis of the bleed-
ing pattern, a smaller number of participants could be
enrolled. Thus, when considering the 80% and 1.6% ame-
norrhea rates for extended use and cyclic use, respectively,
as well as a dropout rate of 35–40%, a statistical power of
80%, and a significance level of 5%, 24 patients would be
sufficient.
The Mann–Whitney test was used to compare the
numbers of days with/without bleeding/spotting during
the total treatment period and the reference periods
between the groups. The bleeding pattern was analyzed
for each 28-day treatment interval in each study group and
compared using the chi-square test. The chi-square test
was also used to compare the rates of amenorrhea (absence
of bleeding or spotting) and absence of bleeding (with or
without spotting) throughout the treatment between the
groups. The analyses were performed using SAS® soft-
ware, version 9.3, and the significance level was 0.05 (α =
5%) for every analysis performed.
Results
Flow through the study is presented in Figure 1 and the
characteristics of the study participants are listed in Table 1.
Among the analyzed variables describing the bleeding
pattern, the number of days without bleeding (light, moderate,
or heavy) throughout the entire evaluation period was signifi-
cantly smaller in the EE/DRSPes group than in the
EE/DRSP24/4 group. On the other hand, the number of days
of spotting was similar between the groups (Figure 2).Women
in the EE/DRSPes group had more days without bleeding or
spotting and fewer days of bleeding or spotting during the
entire treatment period (Table 2). Figure 3 shows the number
of days of bleeding or spotting in both reference periods
analyzed. The number of days of bleeding or spotting in
reference period 1 was significantly lower for the
EE/DRSPes regimen than for the cyclic regimen (P < 0.001).
The result was similar for reference period 2. The percentage
of women who did not experience any sort of bleeding,
including spotting, for each 28-day treatment interval through-
out the entire study period is shown in Figure 4. The rate of
amenorrhea (no bleeding or spotting) associated with the
extended flexible regimen varied by the treatment interval
between 46.5% and 59.5%. This rate was lower among
users of the 24/4 regimen, in whom it varied between 2.6%
and 6.0%. The percentage of women without bleeding or
spotting (i.e., with amenorrhea) was significantly larger in the
EE/DRSPes group than in the EE/DRSP24/4 group for all 6 28-
day treatment intervals (P < 0.001 for every interval). The
same pattern was seen for the rate of bleeding with or without
spotting (Figure 5). The optional 4-day HFI for management
of persistent unexpected bleeding/spotting in women in the
EE/DRSPes group was implemented by 34 women: 23 used it
during 1 interval, 9 during 2 intervals, 1 during 3 intervals, and
1 during 4 treatment intervals. The percentage of women who
are elected to use the HFI to manage persistent unexpected
bleeding/spotting and the percentage in whom this measure is
resolved the bleeding are shown in Figure 6.
Dovepress Bonassi Machado et al
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It is noteworthy that the HFI was effective in every
case in which it was used during treatment intervals 1, 2,




In the present study, we have evaluated an OCP containing
a lower dose of estrogen (20 mcg ethinylestradiol) in com-
bination with drospirenone. The use of this formulation in an
extended regimen significantly reduced the number of days
of bleeding during a 6-month (168-day) period relative to
the use of a cyclic regimen of the same combination.
Differences and Similarities in Relation to
Other Studies
The results shown here agree in part with the findings of
Jensen15 and Klipping,16 who have also evaluated the
same contraceptive composition. While the cyclic group
(24/4 regimen) in our study experienced a median of 15
days of bleeding, both prior studies showed mean values
of 33 and 43 days during 1 and 2 years, respectively.15,16
Although the different study lengths complicate the com-
parison, the mean frequency of total days of bleeding
during the extended regimen was in fact higher in these
2 publications than in our present report. Notably, our
present study assessed the use of the extended regimen
for 168 consecutive days without a programmed pause but
allowed the user to elect a 4-day HFI to manage persistent
unexpected bleeding/spotting; we have termed this mod-
ified treatment schedule the extended flexible regimen.
However, the studies by Jensen et al15 and Klipping et al16
allowed users of their extended regimens to include
a 4-day HFI in case of bleeding for 3 consecutive days
after the first 24 days of use and a scheduled 4-day HFI
after the 120th day, making their regimens flexible
extended regimens of 124 days with management of intra-
cyclic bleeding (flexible MIB regimen). These studies also
included extended use in which the 4-day HFI was
Figure 1 Flow of participants through the trial. EE/DRSPes = ethinylestradiol 20 mcg + drospirenone 3 mg in an extended regimen. EE/DRSP24/4 = ethinylestradiol 20 mcg +
drospirenone 3 mg in a 24/4 regimen.
Bonassi Machado et al Dovepress
submit your manuscript | www.dovepress.com
DovePress




































































Powered by TCPDF (www.tcpdf.org)
allowed regardless of bleeding, with a programmed pause
after the 120th day, defined as a flexible extended regimen
with active period control (flexible APC regimen) and
a fixed extended regimen in which the 4-day HFI was
allowed only after every 120 days of use. The mandatory
contraceptive pause every 4 months and the greater like-
lihood that the user would experience an HFI during the
flexible MIB and APC regimens may explain the greater
mean frequencies of bleeding days relative to the study
length than observed in our study. The extended regimen
that we evaluated also allows flexibility, particularly
regarding the possibility of an HFI, but does not include
a mandatory HFI after 120 days of use.
As seen by other authors,15,16 the extended regimen
decreased the rate of bleeding/spotting relative to that
observed under the 24/4 cyclic regimen, resulting in sig-
nificantly more days free of bleeding/spotting and fewer
days of bleeding in reference periods 1 and 2.
The extended regimen produced significantly higher
rates of absence of bleeding and/or spotting and absence
Table 1 Summary of Demographic and Baseline Characteristics






Age (years) 27.8 (6.1) 27.9 (5.8) 0.921
Marital status – n (%)
Married 54 (31.0) 62 (35.6)
Single 117 (67.2) 107 (61.5)
Divorced/separated 3 (1.7) 5 (2.9)
Age at menarche
(years)
12.7 (1.6) 12.4 (1.3) 0.152
Length of menstrual
cycle (days)




4.5 (1.2) 4.5 (1.1) 0.851
OCP users – n (%) 94 (54.0) 88 (50.6) 0.631
Weight (kg) 62.7 (10.6) 64.2 (9.5) 0.146
BMI (kg/m2) 24.1 (3.5) 24.6 (3.4) 0.183
SBP (mmHg) 111.0 (10.2) 110.7 (9.4) 0.756
DBP (mmHg) 71.0 (8.2) 71.0 (8.1) 0.974
Note: Values presented as the mean (standard deviation) except where indicated.
Abbreviations: OCP, oral contraceptive pill; BMI, body mass index; SBP, systolic
blood pressure; DBP, diastolic blood pressure.
Figure 2 Number of days in the total treatment period (ITT, n = 309) with spotting
only or bleeding only.
Table 2 Median Number of Days During the Entire Treatment
Period (ITT, n = 309) Without Bleeding/Spotting, with Bleeding/
Spotting, and with Bleeding of Each Intensity Level




With bleeding/spotting 17 26 0.004
Spotting 9 10 0.784
Mild bleeding 3 9 < 0.001
Moderate bleeding 0 3 < 0.001
Heavy bleeding 0 0 0.096
A
B
Figure 3 Numbers of days with bleeding or spotting, spotting only, and bleeding
only in the 2 90-day reference periods in both groups. (A) Reference Period 1
(RP 1); (B) Reference Period 2 (RP 2).
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of bleeding (with or without spotting) than did the cyclic
regimen. During the 6th treatment interval, the rate of
absence of bleeding/spotting (amenorrhea) was 57.6%
and the rate of absence of bleeding (with or without spot-
ting) was 73.9%. These findings were compatible with the
usual rates of amenorrhea reported among users of
continuous or extended regimens of OCPs. The rate of
absence of bleeding (with or without spotting) after the
6th month of uninterrupted use of the combination of
ethinylestradiol 30 mcg/gestodene 75 mcg is 81%, almost
the same as that observed with continuous use of ethiny-
lestradiol 20 mcg/levonorgestrel 90 mcg, whereas the
combination of EE 30 mcg/DRSP 3 mg produces a rate
of absence of bleeding (with or without spotting) after the
6th month of around 78%.8–10
Users of extended or continuous regimens of OCPs are
more susceptible to treatment interruption due to unpre-
dictable bleeding than are women who use contraceptives
in the conventional cyclic regimen.17 For this reason,
appropriate pre-treatment counseling, and instruction in
proper management of bleeding during the use of oral
contraceptives according to non-standard schedules of
administration are fundamental to improving the success,
adherence to, and continuity of the use of such contra-
ceptive regimens. In this study, we evaluated the effective-
ness of an HFI in cases of persistent unexpected bleeding
or spotting. Unlike women in previous studies,15,16 the
participants in our study were allowed to choose whether
to implement an HFI to manage unexpected bleeding or
spotting. We observed a small number of women who
instituted the 4-day HFI as a consequence of persistent
unexpected bleeding/spotting. This finding suggests that
persistent unexpected bleeding/spotting during extended
use was uncommon; we can also assume that each
woman’s individual interpretation of unexpected bleed-
ing/spotting was different, making it difficult to establish
quantitatively the best interval for a scheduled HFI.
Furthermore, these findings lead us to question the advan-
tages of flexible regimens with a predetermined HFI (for
example, after 120 days) because although this interval
model is associated with lower rates of unpredictable
bleeding, the withdrawal bleeding produced may not be
necessary for motivated women who have been counseled
regarding bleeding during extended use of OCPs.
For the management of persistent unexpected bleeding/
spotting, we used the HFI described by Sulak et al18 in
a study involving the extended use of a combination of
ethinylestradiol and drospirenone. In the present study, we
observed that the 4-day HFI resolved persistent unex-
pected bleeding/spotting in 94% of the cases in which it
was implemented over the 168 days of the extended use
regimen, proving the effectiveness of this simple measure
for control of unexpected bleeding/spotting.
Figure 4 Percentage of women exhibiting amenorrhea (neither spotting nor
bleeding) during each of the 6 28-day treatment intervals. Between-groups differ-
ence, P < 0.001.
Figure 5 Percentage of women without bleeding (with or without spotting) during
each of the 6 28-day treatment intervals. Between-groups difference, P < 0.001.
Figure 6 Percentage of women in the EE/DRSPes group who implemented the
4-day HFI for management unexpected bleeding/spotting and the rate of effective-
ness thereof during each of the 6 28-day treatment intervals.
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Strengths and Weaknesses of the Study
We consider the strong points of this study to be the large
sample population and the choice of an extended regimen
allowing an optional HFI (also called extended scheduled
regimen) at the woman’s discretion, making the clinical
evaluation closer to a “real-life” scenario. The main lim-
itation of our study is the follow-up time, which is shorter
than in other studies that assessed the use of the same
formulation according to an extended regimen.15,16
Conclusion
In conclusion, the bleeding pattern in women using an
extended regimen of ethinylestradiol 20 mcg and drospir-
enone 3 mg showed no bleeding rates comparable to other
contraceptive formulations, including those with higher
doses of the estrogen component. Elective use of a 4-day
HFI was an efficient way to manage unexpected bleeding/
spotting, allowing control of the unpredictable bleeding
associated with the use of an extended flexible regimen.
Data Sharing Statement
All data from the current study, including individual data
from unidentified patients, are filed by the author and may
be made available at any time, also highlighting that all
data from the full clinical report are available in
Portuguese.
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